JP2010516235A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010516235A5 JP2010516235A5 JP2009545932A JP2009545932A JP2010516235A5 JP 2010516235 A5 JP2010516235 A5 JP 2010516235A5 JP 2009545932 A JP2009545932 A JP 2009545932A JP 2009545932 A JP2009545932 A JP 2009545932A JP 2010516235 A5 JP2010516235 A5 JP 2010516235A5
- Authority
- JP
- Japan
- Prior art keywords
- qpct
- mouse
- transgene
- human animal
- transgenic non
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108700019146 Transgenes Proteins 0.000 claims 20
- 230000009261 transgenic effect Effects 0.000 claims 19
- 238000000034 method Methods 0.000 claims 15
- 108010044467 Isoenzymes Proteins 0.000 claims 8
- 239000003795 chemical substances by application Substances 0.000 claims 7
- 239000012634 fragment Substances 0.000 claims 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 5
- 230000000694 effects Effects 0.000 claims 5
- 229920001184 polypeptide Polymers 0.000 claims 5
- 102000004196 processed proteins & peptides Human genes 0.000 claims 5
- 108090000765 processed proteins & peptides Proteins 0.000 claims 5
- 108090000623 proteins and genes Proteins 0.000 claims 5
- 241001465754 Metazoa Species 0.000 claims 4
- 206010028980 Neoplasm Diseases 0.000 claims 4
- 208000010877 cognitive disease Diseases 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 4
- 208000027061 mild cognitive impairment Diseases 0.000 claims 4
- 208000024827 Alzheimer disease Diseases 0.000 claims 3
- 125000003275 alpha amino acid group Chemical group 0.000 claims 3
- 210000004027 cell Anatomy 0.000 claims 3
- 102000003642 glutaminyl-peptide cyclotransferase Human genes 0.000 claims 3
- 108010081484 glutaminyl-peptide cyclotransferase Proteins 0.000 claims 3
- 102000004169 proteins and genes Human genes 0.000 claims 3
- 238000011830 transgenic mouse model Methods 0.000 claims 3
- 208000023697 ABri amyloidosis Diseases 0.000 claims 2
- 208000017227 ADan amyloidosis Diseases 0.000 claims 2
- 208000030507 AIDS Diseases 0.000 claims 2
- 201000001320 Atherosclerosis Diseases 0.000 claims 2
- 201000010374 Down Syndrome Diseases 0.000 claims 2
- 208000023105 Huntington disease Diseases 0.000 claims 2
- 201000000162 ITM2B-related cerebral amyloid angiopathy 1 Diseases 0.000 claims 2
- 201000000194 ITM2B-related cerebral amyloid angiopathy 2 Diseases 0.000 claims 2
- 201000004681 Psoriasis Diseases 0.000 claims 2
- 230000024932 T cell mediated immunity Effects 0.000 claims 2
- 206010052779 Transplant rejections Diseases 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 208000019425 cirrhosis of liver Diseases 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 230000028996 humoral immune response Effects 0.000 claims 2
- 230000002757 inflammatory effect Effects 0.000 claims 2
- 230000023404 leukocyte cell-cell adhesion Effects 0.000 claims 2
- 230000005012 migration Effects 0.000 claims 2
- 238000013508 migration Methods 0.000 claims 2
- 230000009826 neoplastic cell growth Effects 0.000 claims 2
- 230000004770 neurodegeneration Effects 0.000 claims 2
- 208000005069 pulmonary fibrosis Diseases 0.000 claims 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 2
- 238000012216 screening Methods 0.000 claims 2
- 208000011580 syndromic disease Diseases 0.000 claims 2
- 206010003840 Autonomic nervous system imbalance Diseases 0.000 claims 1
- 208000012639 Balance disease Diseases 0.000 claims 1
- 208000005145 Cerebral amyloid angiopathy Diseases 0.000 claims 1
- 108020004414 DNA Proteins 0.000 claims 1
- 206010012289 Dementia Diseases 0.000 claims 1
- 208000030814 Eating disease Diseases 0.000 claims 1
- 208000019454 Feeding and Eating disease Diseases 0.000 claims 1
- 206010019375 Helicobacter infections Diseases 0.000 claims 1
- 206010023421 Kidney fibrosis Diseases 0.000 claims 1
- 208000009829 Lewy Body Disease Diseases 0.000 claims 1
- 201000002832 Lewy body dementia Diseases 0.000 claims 1
- 206010027476 Metastases Diseases 0.000 claims 1
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 1
- 208000028017 Psychotic disease Diseases 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 206010044688 Trisomy 21 Diseases 0.000 claims 1
- 208000025865 Ulcer Diseases 0.000 claims 1
- 239000013543 active substance Substances 0.000 claims 1
- 230000001668 ameliorated effect Effects 0.000 claims 1
- 206010002022 amyloidosis Diseases 0.000 claims 1
- 230000037007 arousal Effects 0.000 claims 1
- 230000033228 biological regulation Effects 0.000 claims 1
- 210000001185 bone marrow Anatomy 0.000 claims 1
- 230000004663 cell proliferation Effects 0.000 claims 1
- 208000026106 cerebrovascular disease Diseases 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 235000014632 disordered eating Nutrition 0.000 claims 1
- 230000008482 dysregulation Effects 0.000 claims 1
- 210000003038 endothelium Anatomy 0.000 claims 1
- 230000037149 energy metabolism Effects 0.000 claims 1
- 239000012530 fluid Substances 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 230000003284 homeostatic effect Effects 0.000 claims 1
- 230000003054 hormonal effect Effects 0.000 claims 1
- 230000001771 impaired effect Effects 0.000 claims 1
- 238000001727 in vivo Methods 0.000 claims 1
- 208000000509 infertility Diseases 0.000 claims 1
- 230000036512 infertility Effects 0.000 claims 1
- 231100000535 infertility Toxicity 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 230000003211 malignant effect Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 230000009401 metastasis Effects 0.000 claims 1
- 230000000926 neurological effect Effects 0.000 claims 1
- 150000007523 nucleic acids Chemical group 0.000 claims 1
- 230000001717 pathogenic effect Effects 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 201000002793 renal fibrosis Diseases 0.000 claims 1
- 208000037803 restenosis Diseases 0.000 claims 1
- 201000000980 schizophrenia Diseases 0.000 claims 1
- 210000000130 stem cell Anatomy 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 230000001629 suppression Effects 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- 210000001519 tissue Anatomy 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US88564907P | 2007-01-19 | 2007-01-19 | |
| PCT/EP2008/050532 WO2008087197A1 (en) | 2007-01-19 | 2008-01-18 | In vivo screening models for treatment of alzheimer's disease and other qpct-related disorders |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2010516235A JP2010516235A (ja) | 2010-05-20 |
| JP2010516235A5 true JP2010516235A5 (enExample) | 2011-03-03 |
Family
ID=39271322
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009545932A Pending JP2010516235A (ja) | 2007-01-19 | 2008-01-18 | アルツハイマー病及び他のｑｐｃｔ関連障害の治療のためのインビボスクリーニングモデル |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20080200567A1 (enExample) |
| EP (2) | EP2121944B1 (enExample) |
| JP (1) | JP2010516235A (enExample) |
| AT (1) | ATE521711T1 (enExample) |
| AU (1) | AU2008206936B2 (enExample) |
| CA (1) | CA2675192A1 (enExample) |
| DK (1) | DK2121944T3 (enExample) |
| ES (1) | ES2372229T3 (enExample) |
| HR (1) | HRP20110651T1 (enExample) |
| NZ (1) | NZ578513A (enExample) |
| SI (1) | SI2121944T1 (enExample) |
| WO (1) | WO2008087197A1 (enExample) |
| ZA (1) | ZA200904353B (enExample) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9277737B2 (en) | 2006-09-21 | 2016-03-08 | Probiodrug Ag | Mouse models carrying a knock-out mutation of the QPCTL-gene |
| US7803810B2 (en) * | 2007-03-09 | 2010-09-28 | Probiodrug Ag | Inhibitors |
| US9656991B2 (en) * | 2007-04-18 | 2017-05-23 | Probiodrug Ag | Inhibitors of glutaminyl cyclase |
| DK2160380T3 (da) * | 2007-04-18 | 2014-06-30 | Probiodrug Ag | Cyano-guanidin derivater som glutaminyl cyclase inhibitorer |
| US8772508B2 (en) * | 2007-04-18 | 2014-07-08 | Probiodrug Ag | Inhibitors of glutaminyl cyclase |
| US8202897B2 (en) * | 2007-04-18 | 2012-06-19 | Probiodrug Ag | Inhibitors of glutaminyl cyclases |
| US9512082B2 (en) * | 2007-04-18 | 2016-12-06 | Probiodrug Ag | Inhibitors of glutaminyl cyclase |
| WO2008128982A1 (en) * | 2007-04-18 | 2008-10-30 | Probiodrug Ag | Thioxoquinazolinone derivatives as glutaminyl cyclase inhibitors |
| JP5676249B2 (ja) * | 2007-04-20 | 2015-02-25 | プロビオドルグ エージー | グルタミニルシクラーゼ阻害剤としてのアミノピリジン誘導体 |
| EP2195336B1 (en) * | 2007-09-12 | 2015-01-21 | Probiodrug AG | Transgenic mice |
| EP2238252B1 (en) * | 2008-01-14 | 2013-07-31 | Probiodrug AG | Mouse models carrying a knock-out mutation of the glutaminyl cyclase gene |
| NZ590658A (en) * | 2008-07-31 | 2012-07-27 | Probiodrug Ag | Glutaminyl cyclase as a diagnostic / prognostic indicator for neurodegenerative diseases |
| US11219696B2 (en) * | 2008-12-19 | 2022-01-11 | Nationwide Children's Hospital | Delivery of polynucleotides using recombinant AAV9 |
| US8409837B2 (en) | 2010-08-19 | 2013-04-02 | Probiodrug Ag | Crystal structure of glutaminyl cyclase |
| WO2012028706A1 (en) | 2010-09-02 | 2012-03-08 | Probiodrug Ag | IN VIVO SCREENING MODELS FOR TREATMENT OF isoQC-RELATED DISORDERS |
| US8741614B2 (en) | 2010-11-02 | 2014-06-03 | Probiodrug Ag | Crystal structure of isoglutaminyl cyclase |
| US20130052203A1 (en) | 2011-08-12 | 2013-02-28 | Probiodrug Ag | In vivo screening models for treatment of qc-related disorders |
| EP3769789A1 (en) | 2012-08-01 | 2021-01-27 | Nationwide Children's Hospital | Intrathecal delivery of recombinant adeno-associated virus 9 |
| WO2017079547A2 (en) * | 2015-11-04 | 2017-05-11 | The Scripps Research Institute | Compositions and methods for treating cystic fibrosis |
| MC200185B1 (fr) | 2016-09-16 | 2017-10-04 | Coronal Audio | Dispositif et procédé de captation et traitement d'un champ acoustique tridimensionnel |
| MC200186B1 (fr) | 2016-09-30 | 2017-10-18 | Coronal Encoding | Procédé de conversion, d'encodage stéréophonique, de décodage et de transcodage d'un signal audio tridimensionnel |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4873191A (en) | 1981-06-12 | 1989-10-10 | Ohio University | Genetic transformation of zygotes |
| JP2874751B2 (ja) | 1986-04-09 | 1999-03-24 | ジェンザイム・コーポレーション | 希望する蛋白質をミルク中へ分泌する遺伝子移植動物 |
| US4873316A (en) | 1987-06-23 | 1989-10-10 | Biogen, Inc. | Isolation of exogenous recombinant proteins from the milk of transgenic mammals |
| US5175384A (en) | 1988-12-05 | 1992-12-29 | Genpharm International | Transgenic mice depleted in mature t-cells and methods for making transgenic mice |
| GB8901778D0 (en) | 1989-01-27 | 1989-03-15 | Univ Court Of The University O | Manipulatory technique |
| US5602299A (en) | 1992-09-23 | 1997-02-11 | Mount Sinai School Of Medicine Of The City University Of New York | Transgenic animal models for neurodegenerative disease |
| JPH07132033A (ja) | 1993-11-12 | 1995-05-23 | Hoechst Japan Ltd | アルツハイマー病モデルトランスジェニック動物 |
| US6066778A (en) | 1996-11-06 | 2000-05-23 | The Regents Of The University Of Michigan | Transgenic mice expressing APC resistant factor V |
| US5981830A (en) | 1997-05-30 | 1999-11-09 | Schering Aktiengesellschaft | Knockout mice and their progeny with a disrupted hepsin gene |
| US6948038B2 (en) * | 2001-07-24 | 2005-09-20 | Microsoft Corporation | System and method for backing up and restoring data |
| MXPA05011861A (es) | 2003-05-05 | 2006-02-17 | Probiodrug Ag | Uso de efectores de ciclasas de glutamato y glutaminil. |
| US7371871B2 (en) * | 2003-05-05 | 2008-05-13 | Probiodrug Ag | Inhibitors of glutaminyl cyclase |
| NZ572274A (en) * | 2003-05-05 | 2009-06-26 | Probiodrug Ag | Use of effectors of glutaminyl and glutamate cyclases |
| CA2544573A1 (en) * | 2003-11-03 | 2005-06-02 | Probiodrug Ag | Combinations useful for the treatment of neuronal disorders |
| KR101099206B1 (ko) * | 2004-02-05 | 2011-12-27 | 프로비오드룩 아게 | 신규한 글루타미닐 시클라제 저해제 |
| GB0704100D0 (en) | 2006-03-17 | 2007-04-11 | Vodafone Plc | Improvements in an ehspa architecture |
| US20080249083A1 (en) * | 2006-09-21 | 2008-10-09 | Probiodrug Ag | Novel genes related to glutaminyl cyclase |
-
2008
- 2008-01-18 HR HR20110651T patent/HRP20110651T1/hr unknown
- 2008-01-18 CA CA002675192A patent/CA2675192A1/en not_active Abandoned
- 2008-01-18 NZ NZ578513A patent/NZ578513A/en not_active IP Right Cessation
- 2008-01-18 ZA ZA200904353A patent/ZA200904353B/xx unknown
- 2008-01-18 JP JP2009545932A patent/JP2010516235A/ja active Pending
- 2008-01-18 AU AU2008206936A patent/AU2008206936B2/en not_active Ceased
- 2008-01-18 DK DK08707977.8T patent/DK2121944T3/da active
- 2008-01-18 EP EP08707977A patent/EP2121944B1/en not_active Not-in-force
- 2008-01-18 AT AT08707977T patent/ATE521711T1/de active
- 2008-01-18 WO PCT/EP2008/050532 patent/WO2008087197A1/en not_active Ceased
- 2008-01-18 ES ES08707977T patent/ES2372229T3/es active Active
- 2008-01-18 US US12/016,266 patent/US20080200567A1/en not_active Abandoned
- 2008-01-18 SI SI200830434T patent/SI2121944T1/sl unknown
- 2008-01-18 EP EP11178419A patent/EP2395095A1/en not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010516235A5 (enExample) | ||
| JP7755699B2 (ja) | ヒト化ＩＬ－４およびＩＬ－４Ｒα動物 | |
| JP2011501652A5 (enExample) | ||
| ES2715949T3 (es) | Animales con IL-15 humanizada | |
| HRP20110651T1 (hr) | Modeli pretraživanja in vivo radi liječenja alzheimerove bolesti i drugih poremećaja povezanih s qpct | |
| FI3823443T3 (fi) | Ditra-taudin jyrsijämallit ja niiden käyttö | |
| JP2011500007A5 (enExample) | ||
| JP2021169461A (ja) | 寿命に関する動物モデル並びに寿命を延ばす及び腫瘍化を阻害する関連方法 | |
| JP2011509093A5 (enExample) | ||
| Santander et al. | Lack of Flvcr2 impairs brain angiogenesis without affecting the blood-brain barrier | |
| JP2019505216A5 (enExample) | ||
| US7312079B1 (en) | Variants of FAM3C | |
| CN114835798B (zh) | Cd36基因人源化非人动物的构建方法及应用 | |
| EP2241628B1 (en) | Double knockout GABAA alpha 1-/-; CaV3.1 and GABAA alpha 1-/-; Emx1-cre mouse models with enhanced essential tremor | |
| JPWO2009013794A1 (ja) | インスリン分泌誘導剤及び膵臓β細胞増加促進剤 | |
| JP2013541938A (ja) | アイソｑｃ関連障害の治療のためのインビボスクリーニングモデル | |
| Yan et al. | 3.077 Novel PLA2G6 gene mutation is associated with autosomal recessive early-onset parkinsonism | |
| Rida et al. | Exploring single nucleotide polymorphisms in the KCNQ1 gene associated with cardiac disorders | |
| JP2025508063A (ja) | アルツハイマー病の野生由来マウスモデル | |
| JP2001526030A (ja) | カドヘリン様ポリペプチド、それに関連する方法および組成物 | |
| Laffita et al. | 3.075 UNEXPANDED AND INTERMEDIATE POLYMORPHISMS AT SCA2 LOCUS (ATXN2) IN THE CUBAN POPULATION: EVIDENCES ABOUT THE ORIGIN OF EXPANDED ALLELES | |
| Vishwanathan et al. | 3.076 AN EARLY ONSET SOUTH INDIAN PARKINSON'S DISEASE PATIENT WITH NOVEL C. 798_799INSA MUTATION-A CASE VIGNETTE | |
| Koziorowski et al. | 3.078 THE NOVEL THAP1 GENE MUTATION, CHARACTERIZED BY PHENOTYPICAL HETEROGENEITY | |
| CN121182898A (zh) | 一种il22基因人源化动物的构建方法及应用 | |
| JP2011511622A5 (enExample) |